Famotidine CAS 76824-35-6

Product Description:

Product Name: Famotidine CAS NO: 76824-35-6

Synonyms:

N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine;

Ifada;

motiax;

pepdul;

Chemical & Physical Properties:

Appearance: White to off-white crystalline powder

Assay :≥99.00%

Density: 1.83 g/cm3

Melting Point: 163-164℃

Flash Point: 354.4℃

Water Solubility: 1.1 mg/mL

Vapour Pressure: 0.0±2.0 mmHg at 25℃

Index of Refraction: 1.808

Storage Condition: Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.

Safety Information:

RTECS: UA2300000

Safety Statements: S22-S24/25

HS Code: 2935009090

WGK Germany: 2

Risk Statements: R20/21/22

Hazard Code: T

Famotidine, sold under the trade name Pepcid among others is a histamine H2 receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Unlike cimetidine, the first H2 antagonist, famotidine has no effect on the cytochrome P450 enzyme system, and does not appear to interact with other drugs.

It was discovered in 1979. Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.Target: Histamine H2 ReceptorFamotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). Famotidine Group(2 mg/kg/day) were significantly lower than the equivalent parameters for the Control Group on both the third and seventh days post-surgery. famotidine exerts detrimental effects on the anastomotic bursting pressure and hydroxyproline content of perianastomotic tissues in the colon of rats. famotidine increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. The preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.